1 day-6.82%
1 week-19.61%
Current month-30.51%
1 month-68.46%
3 months-99.97%
1 week 0
Extreme 0.003
0.01
1 month 0
Extreme 0.0018
0.06
Current year 0
Extreme 0.0018
117.84
1 year 0
Extreme 0.0018
117.84
3 years 0
Extreme 0.0018
117.84
5 years 0
Extreme 0.0018
117.84
10 years 0
Extreme 0.0018
117.84
Manager TitleAgeSince
Chief Executive Officer 68 30/05/2026
Corporate Officer/Principal 63 27/09/2017
Director of Finance/CFO 53 26/09/2021
Director TitleAgeSince
Director/Board Member 63 27/09/2017
Director/Board Member 73 02/11/2023
Director/Board Member 47 22/10/2024
Date Insider Type Main position Quantity % Market Cap.
06-21
HRT Financial LP
SellCompany -5,120,480 0.5131%
06-17
HRT Financial LP
OtherCompany 2,406,438 0.2411%
06-16
DRW Securities LLC
SellCompany -126,772 0.0127%
Change 5-day change 1-year change 3-year change Capi.($)
-6.82%-19.61% - - 3.34K
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -1.29%-2.28%+52.07%+213.72% 24.16B
Weighted average by Cap. -0.89%-1.45%+51.26%+177.14%

Financials

2024 2025
Net sales 0.13 0.12 0.11 0.1 0.19 12.78 0.19 1.29 0.51 6.26 0.5 0.49 21.71 0 0 0 0 0 0.3 0 0.03 0.01 0.15 0.01 0.01 0.52
Net income -34.45M -30.23M -27.9M -25.75M -48.81M -3.29B -49.66M -332M -130M -1.61B -129M -127M -5.58B -41.71M -36.61M -33.78M -31.19M -59.1M -3.98B -60.14M -403M -158M -1.95B -157M -153M -6.76B
Net Debt - -
Logo Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.
Employees
26
Date Price Change Volume
10/07/26 US$0.004100 -6.82% 67,737,402
09/07/26 US$0.004400 +37.50% 91,777,420
08/07/26 US$0.003200 -8.57% 50,584,819
07/07/26 US$0.003500 -14.63% 51,803,102
  1. Stock Market
  2. Stocks
  3. ADTX Stock